Webinar | Retrospective RNA-Seq of DD-LPS Clinical Trial Patients Reveals a Potential Biomarker

Retrospective RNA Sequencing of Dedifferentiated Liposarcoma Clinical Trial Patients Reveals a Potential Biomarker of Selinexor Response

RNA sequencing (RNA-Seq) is a powerful and scalable tool for determining the level of gene transcript expression to elucidate the difference in expression patterns between unique sample populations. In this webinar, Dr. Donald Skifter, Sr. Vice President, Genomics at Discovery Life Sciences (Discovery) will discuss a retrospective, exploratory RNA sequencing study performed by Discovery in collaboration with Karyopharm Therapeutics using FFPE dedifferentiated liposarcoma (DD-LPS) tumor samples collected over the course of a multi-center phase II – III selinexor clinical trial in advanced liposarcoma. The outcome of this study exemplifies how precision medicine strategies using retrospective exploratory molecular profiling can facilitate identification of biomarkers that may enable targeting the right therapy to the right patient population.